Business
Spectral AI Announces 2025 First Quarter Financial Results
Q1 Overview Research & Development Revenue of $6.7 MillionImproved Capital Structure Reflected in Cash of $14.1 MillionContinued work on planned De Novo submission to the FDA in the first half of 2025 DALLAS, May 13, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter
About this update from Spectral Ai, Inc.
[{"type":"image","alt":"Spectral AI, Inc.","displaySize":"","headline":null,"caption":"Spectral AI, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":78,"url":"https://media.zenfs.com/en/globenewswire.com/23a9fc91c43a2f0647ed42a9076103ab"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NMHcc5qGUB2OTcJyeAvzUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/23a9fc91c43a2f0647ed42a9076103ab","width":150,"height":78}},"lazy":false},{"type":"text","content":"Q1 Overview","length":11,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Research & Development Revenue of $6.7 Million","length":50,"tagName":"p"}]},{"val":[{"type":"text","content":"Improved Capital Structure Reflected in Cash of $14.1 Million","length":61,"tagName":"p"}]},{"val":[{"type":"text","content":"Continued work on planned De Novo submission to the FDA in the first half of 2025","length":81,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":192,"olType":false},{"type":"text","content":"DALLAS, May 13, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2025 and provided an update on its ongoing business activities.","length":378,"tagName":"p"},{"type":"text","content":"“During the first quarter we continued to execute against our strategic plan and are working hard towards our De Novo submission to the FDA by the end of the first half of 2025,” said Dr. J. Michael DiMaio, M.D., the Company’s Chairman of the Board. “We made important strides in the validation of the diagnostic results of our DeepView™ System for burn indication through the completion of our Burn Validation Study in March, 2025. The goal of the Burn Validation Study was to further demonstrate the innovative and versatile nature of Spectral AI’s DeepView technology, as well as its ability to predict burn wound healing potential on the first day of injury with greater performance and speed than the methods currently used today. With the rigorous statistical analysis support, the DeepView System continues to outperform the clinical judgment of burn physicians b...